Daily Archives: May 30, 2023

Round the Fire: A Love You Cant Defeat – Louisville Eccentric Observer (LEO Weekly)

Posted: May 30, 2023 at 12:10 am

It is said that when a woman has a baby her DNA changes with the creation blooming inside her. She is forever shifted and connected primordially to this new soul. I was 42 when I had my first, and only son. Nothing has gone as planned.

I have always wanted to be a mom but did not think it would happen for me. I married at 38, and we were not sure if a child was an option or if we even wanted to be parents. My mind was already damaged from all the years of social work. I knew exactly what was going on in the world and was unsure I wanted to bring a life into that energy.

We watched our friends families begin, and it was an amazing experience to see growth from the people I love. We knew it would be difficult because I was older and not in the best of health with obesity and some managed health issues. We began our attempts, which lasted about six months before we gave up and I accepted that it was not meant to be for us.

My husband and I decided to plan our future with travel and adventure so we booked our first trip into the woods for our anniversary in June. We would eat, drink, stay naked all day, create, and hang with mother nature to toast to our newly defined future.

I found out that I was pregnant a month before we were to embark on our woodsy celebration of being childfree creatives. When I told my husband, he could not speak and probably saw his, or my death, flash before his eyes. He was speechless, and unnerved. I was not afraid.

I have always wanted to accept life as it was presented to me, and to strive for blessings in whatever situation I found myself in, even if it meant not getting what I wanted or causing strife and challenge to the journey.

For us, our son Vincent, was simply meant to be.

Pregnancy came easy for me aside from some changes in my palate. I was monitored relentlessly for the high risks of being an older mother. For the first time in my life, I felt the feeling of not being alone in the most symbiotic way. This baby relied on me for everything and I spoke to him often a constant dialogue that continues now that hes 12. I shared my fears that I was too old to give him the energy needed for motherhood, and shared my excitement over who he would become. We were both evolving into a new world that was a family.

My scheduled and induced delivery was set and turned into the most unnatural experience of my life. I just wanted both of us to survive. I labored for three days, had different doctors probing around my nether regions, strange devices inserted that meant to force dilation, and chemicals to induce progression for natural delivery. I came to the solution that my cervix was petrified with age as I never progressed beyond four centimeters. It was a nightmare, and my doctor was leaving for vacation to Australia. It was evident that he had already left in his mind.

My husband was reaching critical mass on day three, ready to slam the doctor into the wall for the neglect, but the physician was already on a plane.

Vincents heartbeat weakened and a whole team of people rushed in, rolling me around like bread dough to get the heartbeat back. At that point, Id had enough, did what Ive had to do all of my life without fail and stood up for myself. I demanded to speak to the legal department about why the medical staff was not moving forward with surgery. My politeness left my soul. I found myself in a queue of women also waiting for their surgeries. I distinctly remember thinking this was like waiting at Jiffy Lube for an oil change.

Finally, Vincent came via emergency cesarean by an OB/GYN Id never met.

The only voice I heard throughout was the anesthesiologist. He got me past all the fears that I was not numb enough, and stayed with me through the surgery. I do not remember seeing my husbands face but I had seen many births before and knew he would be forever changed by the experience.

After the tiger cub scream that told the world a new soul was here, Vincent was shown to me like a puppet from behind the sheet separating my head from my body, and then whisked off for all the usual tests and documentation.

I knew at that moment something was going wrong inside me. I felt like I was suffocating. I shared my fears and the voice of the anesthesiologist continued to keep me calm. The countdown for stitches and instrument accountability filled the room. They were in a hurry and I wanted to get off that table and hold my baby.

After some time in recovery, I got my wish. I looked into his squinty eyes and laid him on my chest to make sure he remembered the body that housed him. I could feel myself change as I began healing and bonding with this new little person. My body, forever changed from the experience, was entering another, more perilous journey. This was just the tip of the iceberg.

Here is the original post:

Round the Fire: A Love You Cant Defeat - Louisville Eccentric Observer (LEO Weekly)

Posted in Childfree | Comments Off

No Link Observed Between Gastrointestinal Tract Surgery and New … – MD Magazine

Posted: at 12:10 am

Credit: Unsplash / JAFAR AHMED

Despite a risk of disruption to the microbiome, gastrointestinal tract surgeries are associated with minimal risk of developing psoriasis.1

In new retrospective analysis data from a group of Taiwan investigators, invasive gastrointestinal tract procedures including appendectomy were not significantly associated with increased risk of a new psoriasis diagnosis. The findings additionally elucidated age- and sex-specific risk of new psoriasis diagnoses among such patients.

Led by Dr. Yi-Huei Liu, of the Chung Shan Medical University in Taichung, investigators sought to examine the link between gastrointestinal tract surgery and newly diagnosed psoriasis. Non-genetic psoriasis etiology is not absolutely understood by clinicians, though previous research has pointed to triggers including skin micro-trauma as a potential risk factor for the chronic skin disease.

Whats more, the gut microbiome is a pivotal factor in immune regulation. In a recent interview with HCPLive, dermatologist Karan Lal, DO, MS, described a complex dynamic between chronic skin diseases and microbiota.2

We know that with psoriasis, if they have a leaky gut, they have association with inflammatory bowel disease and a lot of gut issues, Lal said. And so maybe that's why people translate that into the skin microbiome. But again, that's a lot of the people who don't really understand the true relationship with the skin gut axis.

Nonetheless, Liu and colleagues stressed the little-defined association between these potential risk factors and newly diagnosed psoriasis.

Even if surgeries are widely considered a risk factor and disrupt the microbiome in the gastrointestinal tract, resulting in psoriasis, no previous studies have investigated the epidemiological relationship between gastrointestinal tract surgeries and subsequent pathogenesis of psoriasis, they wrote. Therefore, we conducted a nationwide case-control study to explore this issue.

Investigators conducted a nested case-control analysis using data from the Taiwan National Health Insurance Research Database, including patients with newly diagnosed psoriasis from 2005 2013. Their retrospective analysis spanned 5 years after the index date of first psoriasis diagnosis. A control cohort of patients who had never been diagnosed with psoriasis or a similar disorder was matched 2:1 by age and sex to compare the association of concurrent gastrointestinal tract surgery.

The final assessment included 16,655 patients with newly diagnosed psoriasis from 2005 2013. Mean age of both cohorts was 32.2 years old. Chronic diseases including hypertension, diabetes, COPD, and hepatitis C were significantly more prevalent in patients with newly diagnosed psoriasis.

Liu and colleagues conditional logistic regression showed an 8% decreased risk of newly diagnosed psoriasis among patients who underwent gastrointestinal tract surgery (condition odds ratio [cOR], 0.92; 95% CI, 0.76 1.12; P = .426), and a 2% decreased risk of psoriasis among patients who underwent appendectomy (cOR, 0.98; 95% CI, 0.76 1.27; P = .896).

In the multivariate regression analysis of age- and sex-related factors, investigators observed only patients aged 20 39 were at an increased risk of newly diagnosed psoriasis following gastrointestinal tract surgery (OR, 1.09; 95% CI, 0.79 1.51; P = .58), though the association was insignificant. Both male (OR, 0.96; 95%, 0.71 1.29; P = .762) and female (OR, 0.90; 95% CI, 0.69 1.17; P = .427) patients were at an insignificantly decreased risk of newly diagnosed psoriasis after surgery.

Regarding appendectomy, each of patients aged <20 years, 20 39 years, and 40 59 years were at an insignificantly increased risk of newly diagnosed psoriasis after procedure, as well as both female and male patients.

In conclusion, our study shows that gastrointestinal surgeries have a limited effect on psoriasis, investigators wrote. Except for gastrointestinal tract surgery, appendectomy did not have significant age- or sex-related effects on psoriasis.

However, the team stressed that their provisional data based solely on the Taiwan population would require further analysis of additional ethnicities and populations to interpret associations between surgery and psoriasis.

References

View post:
No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine

Posted in Psoriasis | Comments Off

Lynk doses first cohort in Phase Ib trial of psoriasis therapy – Clinical Trials Arena

Posted: at 12:10 am

Lynk Pharmaceuticals has dosed the first cohort of patients in a Phase Ib clinical trial of LNK01004 ointment to treat psoriasis, a chronic inflammatory skin disease.

The study will evaluate preliminary efficacy of LNK01004 in Chinese patients with mild to moderate plaque psoriasis.

It will also assess the safety, tolerability and pharmacokinetic properties of the topical ointment.

Lynk Pharmaceuticals chief development officer Dr Henry Wu said: LNK01004 has already shown good efficacy and safety in preclinical animal studies.

Characterised by scaly erythematous or plaque lesions, psoriasis is an immune-mediated, relapsing skin disease that can be local or widely distributed.

Lifelong treatment is required for psoriasis patients to prevent complications from developing, thereby maintaining their quality of life.

Lynk Pharmaceuticals founder and CEO Dr Zhao-Kui (ZK) Wan said: As a third generation JAK inhibitor, LNK01004 can effectively inhibit psoriasis-related cytokine-induced JAK/STAT signaling pathways in skin tissues by topical application.

Additionally, LNK01004 has the advantage of extremely low exposure in the blood system to potentially avoid safety concerns due to systemic exposure.

In addition to the highly selective JAK1 inhibitor LNK01001, we have also assembled a promising pipeline consisting of multiple third-generation, tissue-restricted soft pan JAK inhibitors in clinical trials including the GI-restricted LNK01003 for UC which is currently in Phase IIa.

Last week, Lynk reported that the Phase II study of LNK01001 for rheumatoid arthritis treatment demonstrated statistically significant differences in efficacy against placebo in primary and key secondary efficacy endpoints. It is actively seeking a partner for developing LNK01001 in markets worldwide.

Read the original post:
Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena

Posted in Psoriasis | Comments Off

Metabolic Inflammation Contributes to Depression in Psoriatic Disease – Dermatology Times

Posted: at 12:10 am

In patients with psoriasis and psoriatic disease, metabolic inflammation is a cause of comorbid depression, according to new research.

A research article1 reported that specific inflammatory patterns within IL-6, IL-8, IL-23, IL-17 family cytokines, and tumor necrosis factor (TNF) can cause neuroinflammation, ultimately leading to anxiety and/or depressive behavior or depression in patients with psoriatic disease. According to authors, prior knowledge of psoriasis and comorbid depression linked burden of disease, psychological stress, and stigmatization to the origins of depression.

Authors noted that non-cutaneous diseases such as diabetes, heart failure, and hypertension were first identified as comorbidities of psoriasis in 1995, with cardio-metabolic consequences related to psoriatic disease being more thoroughly understood over time. Risk of myocardial infarction, for example, was previously found to be significantly higher in patients with psoriasis than in members of the general population.

Other conditions such as dyslipidemia and endothelial dysfunction were also linked to psoriatic disease. Like depression, article authors noted that both comorbid conditions are linked to inflammation.

In western countries, authors note that 1 in 5 people with psoriatic disease, as much as 20%, also experience depression. Previous studies have also demonstrated that rates of depression are higher in patients with psoriatic conditions than in the general population.

Citing recent brain structure research,2 authors described research demonstrating increased right precuneus thickness in people with psoriasis, only in cases where depression was present. Additionally, further research3 demonstrated a positive correlation between psoriasis area and severity index (PASI) and the Zung self-rating depression scale (SDS) in cases of comorbid depression and psoriasis.

Considering that depression is an inflammatory condition with neuroinflammatory events with a similar signature as in the major domains of psoriatic disease, people with psoriasis-associated depression are no longer responsible for their perceived lack of coping with psychological threads, articleauthors wrote. In the practical management of people with psoriatic disease, screening for depression by using simple clinical questions or respective tools needs to be implemented.

References

See the rest here:
Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times

Posted in Psoriasis | Comments Off

Encouraging Diversity and Inclusion for Patients With Psoriatic … – MD Magazine

Posted: at 12:10 am

In an interview with HCPLive Rheumatology, Soumya Chakravarty, MD, PhD, FACP, FACR, Senior Director, Strategic Lead, Janssen Rheumatology, and Daphne Chan, PhD, Head of Dermatology Medical Affairs, Janssen, discussed Janssens commitment to diversity, equity, and inclusion for patients with psoriatic disease.

It has been a fantastic opportunity to emphasize our dedication to advancing care for patients with immune-mediated diseases, especially those with psoriatic disease who belong to communities of color, Chakravarty emphasized. The determination platform we discussed is just one of many ongoing efforts, where we collaborate with various partners to develop specific solutions. It's important to note that this is just the beginning.

Their efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce. They strive to deliver culturally competent care and promote progress in this area.

At Janssen, they have undertaken an extensive analysis of the dermatology and rheumatology landscapes to identify unmet needs so they can take meaningful actions as an industry leader and partner. They make an effort to acknowledge the problems the world faces and are realistic about what they can address. Therefore, they focus on the areas where they can make a difference.

Regarding the VISIBLE study, Chan emphasized that simply conducting the study opens doors to demonstrating how it is possible and why it should become the new standard in trial conduct.

Initially, we were apprehensive and doubted whether it could be done, Chan stated. However, I am pleased to report that even taking that first step has yielded tremendous results and rewards. We surprised ourselves by completing the trial's enrollment 7 times faster than projected, concluding 6 months ahead of schedule.

With the trial recruiting so quickly, they expect to have results available sometime next year.

We will be delighted to re-engage in a conversation about the results and what we are learning about people of color living with psoriasis and psoriatic arthritis, Chan emphasized. This experience sets a new chapter for inclusive research and medical practice, defining how it should be in the future.

This transcript was edited for clarity.

Read the original here:
Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine

Posted in Psoriasis | Comments Off

The Weekly Roundup: May 22-26 – Dermatology Times

Posted: at 12:10 am

Expanding Ethnic Hair Care

In this months Cosmetic Conundrums column, Zoe Diana Draelos, MD, discusses solutions for ethnic and Afro-textured hair care.

A recent study supports a degree of correlation between trough serum concentration of infliximab and clinical response to infliximab in patients with the condition.

Researchers analyzed dermatoses associated with obesity and insulin resistance in pediatric patients.

Renata Block, MMS, PA-C, spearheaded a skin cancer screening event for veterans in her hometown.

As many as 1 in 5 patients with psoriasis experience depression as a comorbidity.

Topline results for the topical sodium channel blocker are expected in 2024.

The adalimumab biosimilar will be commercially available in the US starting July 1, 2023.

The first-of-a-kind product uses a topically applied small peptide fluorescent dye and handheld imager to non-invasively detect a biomarker of early tissue changes.

In part 3 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

New research into the diseases pathogenesis may inform future treatment options.

Cream containing epigallocatechin gallate (EGCG) or EGCG combined with L-carnitine yielded a greater anti-sebum effect.

If you werent able to attend SCALE 2023 or want to review the latest data, our full recap has you covered.

In this weeks Pointers with Portela, the 208SkinDoc gives his best product recommendations for Mother's Day gifts.

The autosomal recessive disorder is primarily caused by mutations in the TGM5 gene and less frequently in the CSTA gene.

While receiving checkpoint inhibitor therapy, patients with advanced melanoma benefitted from a telehealth exercise program.

Click here to answer this week's poll.

The JAK inhibitor demonstrated promising efficacy and safety.

Yuflyma will be available to US patients in July 2023.

The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.

This week's edition of the Mainstream Patient features stories about facial balancing, eyelid surgery 101, dermatologist-recommended sunscreen sticks, and more.

In this months Finance & Practice Management column, we illustrate the importance of developing and maintaining a budget for physicians at all stages of their careers.

Coastal regions require environmentally-protective sun protection measures and best practices.

In patients with high levels of VEGF-A and more severe psoriasis, downregulation of blood vessel area is more abrupt.

Posted in Psoriasis | Comments Off

Pediatric Psoriasis Market: A Study of the Industry’s Key Applications … – The Navajo Post

Posted: at 12:10 am

[Vancouver, Canada, 16-05-2023] Emergen Research, a leading provider of market research solutions, is thrilled to announce the release of its highly anticipated collection of comprehensive market research content. This innovative offering aims to empower businesses across industries with valuable insights and data-driven strategies to drive growth and success.

In todays competitive marketplace, staying ahead of the curve is essential for businesses of all sizes. Understanding consumer behavior, market trends, and emerging opportunities is crucial for making informed decisions and developing effective strategies. Emergen Research recognizes this need and has invested significant resources in developing a cutting-edge market research content library.

The newly launched Pediatric Psoriasis market research content is meticulously crafted by industry experts, leveraging extensive data analysis, and a deep understanding of various markets. This rich collection includes in-depth reports, whitepapers, case studies, trend analyses, and industry insights covering a wide range of sectors, including but not limited to technology, healthcare, finance, consumer goods, and manufacturing.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/52

The global pediatric psoriasis market was valued at USD 9.76 billion in 2019 and is expected to reach USD 21.38 billion by the year 2027, at a CAGR of 10.3%. The global Pediatric psoriasis market is growing at a significant pace owing to the growing demand for therapy for diseases such as pediatric psoriasis, favorable government initiatives followed by intensive product development. Considering the factors such as considering the physical development and rate of cutaneous absorption, treating a child with psoriasis has been a huge challenge. With the advent of technology, research has contributed significantly to the various development of treatment for the disease across the globe. Psoriasis is a life-long devitalizing disease that has a significant impact both emotionally and physically including other aspects of life of children. The prolonged sun exposure makes it more demanding while considering phototherapy in children for the rest of their life. Therefore, long-term treatment of psoriasis, with phototherapy or drugs, needs critical evaluation.

Competitive Landscape:

The latest study provides an insightful analysis of the broad competitive landscape of the global 777 market, emphasizing the key market rivals and their company profiles. A wide array of strategic initiatives, such as new business deals, mergers & acquisitions, collaborations, joint ventures, technological upgradation, and recent product launches, undertaken by these companies has been discussed in the report.

AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck, Boehringer Ingelheim and LEO Pharma

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/52

Market Segmentation:

The report bifurcates the Pediatric Psoriasis market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.

Our goal at Emergen Research is to empower businesses with the knowledge and insights necessary to make informed decisions and thrive in todays dynamic business landscape. Our market research content is designed to equip professionals and organizations with comprehensive analyses, actionable recommendations, and a competitive edge to achieve their growth objectives.

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/52

Target Audience of the Global Pediatric Psoriasis Market Report:

Key features and benefits of Emergen Researchs market research content include:

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/pediatric-psoriasis-market

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Recent Published Reports By Emergen Research: